Last week, The Washington Post reported that pharmaceutical firm Pfizer has data showing that an arthritis treatment it owns called Enbrel may also lower the risk of getting Alzheimer’s by 64 per cent. But, according to critics, Pfizer has elected not to develop the drug for this condition because the patent on it will soon expire, meaning the company won’t profit from pursuing it further.